A Study Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes

PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

401

Participants

Timeline

Start Date

April 30, 2024

Primary Completion Date

August 15, 2025

Study Completion Date

September 22, 2025

Conditions

Adult Patients With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs

Interventions

DRUG

HR17031 injection

DRUG

insulin glargine

Trial Locations (1)

Peking University People's Hospital, Beijing

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT06881264 - A Study Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes | Biotech Hunter | Biotech Hunter